Drug treatment options for irritable bowel syndrome: managing for success (Q34218970)

31 July 2017

1 reference

title

Drug treatment options for irritable bowel syndrome: managing for success (English)

1 reference

31 July 2017

main subject

irritable bowel syndrome

1 reference

Dunphy RC

1

1 reference

31 July 2017

Verne GN

series ordinal

2

1 reference

31 July 2017

publication date

1 January 2001

1 reference

31 July 2017

1 reference

31 July 2017

volume

18

1 reference

31 July 2017

issue

3

1 reference

31 July 2017

page(s)

201-211

1 reference

The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation

31 July 2017

cites work

1 reference

12 December 2020

Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study

1 reference

12 December 2020

Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome. A controlled, crossover study.

1 reference

12 December 2020

1 reference

12 December 2020

American Gastroenterological Association medical position statement: irritable bowel syndrome

1 reference

12 December 2020

Loperamide treatment of the irritable bowel syndrome

1 reference

12 December 2020

Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome

1 reference

12 December 2020

Irritable colon syndrome treated with an antispasmodic drug

1 reference

12 December 2020

Pharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle

1 reference

12 December 2020

Review article: the hypersensitive gut—peripheral kappa agonists as a new pharmacological approach

1 reference

12 December 2020

Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome

1 reference

12 December 2020

Effect of dietary fibre on stools and the transit-times, and its role in the causation of disease

1 reference

12 December 2020

Altered small bowel motility in irritable bowel syndrome is correlated with symptoms.

1 reference

12 December 2020

Insights into the pathophysiology and mechanisms of constipation, irritable bowel syndrome, and diverticulosis in older people

1 reference

12 December 2020

Chinese herbal medicine for irritable bowel syndrome

1 reference

12 December 2020

Altered rectal perception is a biological marker of patients with irritable bowel syndrome.

1 reference

12 December 2020

A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome

1 reference

12 December 2020

Loperamide in treatment of irritable bowel syndrome--a double-blind placebo controlled study

1 reference

12 December 2020

Epidemiology of colonic symptoms and the irritable bowel syndrome

1 reference

12 December 2020

Pre-clinical and clinical pharmacology of selective muscarinic M3 receptor antagonists

1 reference

12 December 2020

An assessment of dicyclomine hydrochloride ('Merbentyl') in the irritable colon syndrome

1 reference

12 December 2020

Review article: clinical pharmacology of alosetron

1 reference

12 December 2020

Somatostatin analog inhibits afferent response to rectal distention in diarrhea-predominant irritable bowel patients.

1 reference

12 December 2020

Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans

1 reference

12 December 2020

Review article: irritable bowel syndrome

1 reference

12 December 2020

Diagnosing and treating patients with refractory functional gastrointestinal disorders

1 reference

12 December 2020

Postinfective diarrhoea and bile acid malabsorption.

1 reference

12 December 2020

Review article: clinical evidence to support current therapies of irritable bowel syndrome

1 reference

12 December 2020

U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact

1 reference

12 December 2020

Functional bowel disorders and functional abdominal pain

1 reference

12 December 2020

Diet and the irritable bowel syndrome

1 reference

12 December 2020

Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience

1 reference

12 December 2020

NMDA and quisqualate modulation of visceral nociception in the rat.

1 reference

12 December 2020

Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome

1 reference

12 December 2020

Irritable bowel syndrome: a technical review for practice guideline development

1 reference

12 December 2020

Antidepressants for functional gastrointestinal syndromes.

1 reference

12 December 2020

Effects of tricyclic antidepressants on mechanosensitive pelvic nerve afferent fibers innervating the rat colon

1 reference

12 December 2020

Intracolonic zymosan produces visceral hyperalgesia in the rat that is mediated by spinal NMDA and non-NMDA receptors

1 reference

12 December 2020

The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome

1 reference

12 December 2020

Tolerance for rectosigmoid distention in irritable bowel syndrome

1 reference

12 December 2020

The irritable bowel syndrome: mechanisms and a practical approach to management

1 reference

12 December 2020

The GI drug column. The ACG committee on FDA related matters

1 reference

12 December 2020

Zamifenacin (UK‐76, 654), a potent gut M3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome

1 reference

12 December 2020

Role of loperamide and placebo in management of irritable bowel syndrome (IBS)

1 reference

12 December 2020

Bran and irritable bowel syndrome: time for reappraisal

1 reference

12 December 2020

Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial.

1 reference

12 December 2020

Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome

1 reference

12 December 2020

"Prokinetic" treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride.

1 reference

12 December 2020

Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride)

1 reference

12 December 2020

The value of prescribed 'high-fibre' diets for the treatment of the irritable bowel syndrome

1 reference

12 December 2020

Evidence for exacerbation of irritable bowel syndrome during menses

1 reference

12 December 2020

Towards positive diagnosis of the irritable bowel

1 reference

12 December 2020

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist

1 reference

12 December 2020

Review article: an integrated approach to the irritable bowel syndrome

1 reference

12 December 2020

Functional gut disorders: from motility to sensitivity disorders. A review of current and investigational drugs for their management

1 reference

12 December 2020

Therapy of irritable bowel syndrome--an overview

1 reference

12 December 2020

10.2165/00002512-200118030-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1043239525

0 references

1 reference